AI Insight
Researchers used CRISPR gene-editing technology to remove the CD33 protein from donor stem cells before transplantation in blood cancer patients. This modification allows doctors to use CD33-targeted cancer treatments that would normally destroy both cancerous and healthy blood cells. In a clinical trial of 30 patients, the genetically edited stem cells successfully engrafted and protected healthy blood cells from the CD33-targeting therapy.
Why it matters
This approach could make aggressive blood cancer treatments safer and more effective by protecting transplanted healthy cells while still attacking cancer cells. The technique may reduce complications from bone marrow transplants and expand treatment options for patients with difficult-to-treat blood cancers.
Understand the Science
Researchers used CRISPR to remove CD33 from donor stem cells, potentially giving doctors a way to attack aggressive blood cancers without destroying the healthy cells patients need after a transplant. In a 30-patient trial, the edited cells successfully took hold and appeared to shield blood cells from a CD33-targeted cancer treatment.
Source: CRISPR could help doctors attack blood cancer without destroying healthy cells